
Annual report 2025
added 02-03-2026
Intuitive Surgical Financial Ratios 2011-2026 | ISRG
Annual Financial Ratios Intuitive Surgical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
59.9 | 87.5 | 74.0 | 65.8 | 60.7 | 81.3 | 47.8 | 51.3 | 72.4 | 35.9 | 34.1 | 43.6 | 24.9 | 34.7 | 36.1 |
P/S |
17.0 | 24.3 | 18.7 | 14.0 | 18.1 | 19.8 | 14.7 | 15.5 | 15.3 | 9.8 | 8.4 | 8.6 | 7.4 | 10.5 | 10.2 |
EPS |
8 | 6.5 | 5.1 | 3.7 | 4.8 | 3.0 | 4.0 | 9.9 | 6.0 | 6.4 | 5.3 | 11.3 | 17.1 | 16.5 | 12.6 |
EV (Enterprise Value) |
170 B | 203 B | 132 B | 87.3 B | 104 B | 86 B | 66.2 B | 58.1 B | 48.2 B | 26.1 B | 19.9 B | 18.2 B | 16.4 B | 22.7 B | 17.8 B |
EBITDA per Share |
9.93 | 7.85 | 6.12 | 5.35 | 5.9 | 3.62 | 13.7 | 11.6 | 10.3 | 9.03 | 7.45 | 5.59 | 7.64 | 7.84 | 6.3 |
EV/EBITDA |
49.3 | 67.5 | 41.0 | 43.1 | 40.9 | 24.5 | 23.3 | 28.5 | 17.3 | 23.8 | 23.5 | ||||
PEG |
2.44 | 19.19 | 30.62 | 31.99 | 8.92 | -51.87 | 2.33 | 0.76 | -9.4 | 1.71 | 0.86 | -1.35 | 17.85 | 1.13 | 1.22 |
P/B |
9.5 | 12.3 | 9.9 | 7.8 | 8.7 | 8.8 | 8.0 | 8.6 | 10.1 | 4.6 | 4.6 | 5.4 | 4.8 | 6.4 | 6.8 |
P/CF |
56.4 | 84.2 | 73.4 | 58.4 | 49.5 | 58.1 | 56.2 | 58.9 | 50.1 | 26.7 | 29.0 | 32.6 | 21.5 | 33.9 | 30.1 |
ROE % |
16.02 | 14.13 | 13.42 | 11.90 | 14.26 | 10.87 | 16.65 | 16.87 | 13.96 | 12.74 | 13.63 | 12.39 | 19.16 | 18.34 | 18.71 |
ROA % |
13.96 | 12.39 | 11.64 | 10.19 | 12.58 | 9.50 | 14.17 | 14.37 | 11.46 | 11.34 | 12.00 | 10.58 | 16.99 | 16.18 | 16.16 |
ROCE % |
16.53 | 14.29 | 13.19 | 14.19 | 15.24 | 10.76 | 15.79 | 17.07 | 20.87 | 16.05 | 16.76 | 15.75 | 23.88 | 24.01 | 25.33 |
Current Ratio |
8.1 | 8.5 | 7.6 | 7.0 | 8.5 | 7.9 | 4.5 | 5.3 | 4.0 | 5.4 | 4.5 | 3.7 | 5.1 | 4.7 | 4.6 |
DSO |
49.9 | 51.5 | 53.1 | 50.6 | 45.6 | 54.0 | 52.6 | 66.9 | 59.7 | 58.1 | 60.4 | 54.0 | 48.6 | 62.0 | 61.9 |
DIO |
177.4 | 181.8 | 161.1 | 133.3 | 123.8 | 145.9 | 158.9 | 133.3 | 94.2 | 81.7 | 76.0 | 92.4 | 97.7 | 72.9 | 84.6 |
DPO |
23.9 | 25.7 | 25.6 | 24.2 | 21.1 | 25.0 | 32.9 | 32.8 | 32.2 | 30.7 | 23.8 | 31.3 | 25.1 | 34.6 | 34.6 |
Operating Cycle |
227.3 | 233.3 | 214.2 | 183.9 | 169.5 | 199.9 | 211.4 | 200.1 | 153.9 | 139.8 | 136.3 | 146.3 | 146.3 | 134.9 | 146.5 |
Cash Conversion Cycle |
203.4 | 207.6 | 188.6 | 159.8 | 148.4 | 174.9 | 178.5 | 167.3 | 121.7 | 109.1 | 112.5 | 115.0 | 121.1 | 100.4 | 111.9 |
All numbers in USD currency
Quarterly Financial Ratios Intuitive Surgical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.98 | 1.84 | 1.95 | - | 1.59 | 1.48 | 1.54 | - | 1.18 | 1.2 | 1.01 | - | 0.91 | - | 1.02 | 1.07 | 1.07 | 1.45 | 1.2 | 3.11 | 2.68 | 0.58 | 2.69 | 3.09 | 3.44 | 2.76 | 2.67 | 2.56 | 2.57 | 2.25 | 2.55 | -0.28 | 2.67 | 2.01 | 1.62 | 1.75 | 1.82 | 1.61 | 1.21 | 5.09 | 4.49 | 3.64 | 2.64 | 4.03 | 3.43 | 2.82 | 1.16 | 4.36 | 4.06 | 3.99 | 4.69 | 4.37 | 4.59 | 3.88 | 3.63 | 3.86 | 3.13 | 2.99 | 2.66 |
EBITDA per Share |
2.14 | 2.08 | 1.63 | - | 1.63 | 1.61 | 1.34 | - | 1.34 | 1.33 | 1.12 | - | 1.14 | - | 1.16 | - | 1.26 | 4.37 | 1.36 | - | 1.22 | 1.57 | 2.87 | - | 4.1 | 3.7 | 2.47 | - | 3.42 | 2.88 | 2.66 | - | 3.06 | 2.7 | 1.9 | - | 2.67 | 7.35 | 5.23 | - | 6.33 | 5.49 | 3.93 | - | 5.47 | 4.55 | 1.8 | - | 5.36 | 6.01 | 6.49 | - | 5.93 | 6.03 | 5.08 | - | 5.11 | 4.64 | 3.97 |
ROE % |
15.54 | 14.98 | 14.85 | 11.04 | 14.34 | 14.03 | 13.98 | 9.96 | 12.76 | 12.26 | 11.75 | 8.81 | 12.01 | 9.53 | 14.30 | 15.49 | 16.04 | 15.95 | 11.88 | 10.90 | 11.47 | 13.05 | 16.20 | 16.69 | 16.74 | 16.32 | 16.29 | 16.89 | 11.85 | 13.72 | 14.56 | 14.04 | 18.23 | 15.63 | 14.16 | 12.74 | 13.60 | 13.83 | 13.75 | 13.63 | 13.58 | 13.36 | 13.33 | 12.39 | 12.80 | 13.61 | 15.08 | 19.16 | 19.30 | 19.94 | 19.73 | 18.34 | 19.17 | 18.68 | 18.79 | 18.71 | 4.63 | 4.44 | 3.93 |
ROA % |
13.72 | 13.27 | 13.17 | 9.79 | 12.62 | 12.26 | 11.82 | 8.27 | 10.71 | 7.61 | 10.28 | 7.79 | 10.60 | 8.42 | 12.63 | 13.65 | 14.11 | 13.98 | 10.38 | 9.50 | 9.90 | 11.17 | 13.83 | 14.17 | 14.22 | 13.87 | 13.86 | 14.37 | 10.10 | 11.54 | 12.15 | 11.61 | 15.30 | 13.39 | 12.37 | 11.34 | 12.07 | 12.23 | 12.12 | 12.00 | 11.83 | 11.55 | 11.44 | 10.58 | 11.08 | 11.92 | 13.32 | 16.99 | 17.09 | 17.63 | 17.42 | 16.18 | 16.80 | 16.28 | 16.30 | 16.16 | 4.00 | 3.83 | 3.40 |
ROCE % |
- | - | - | - | - | - | - | - | 3.45 | 6.89 | 10.25 | 10.16 | 14.02 | 11.08 | 15.80 | 12.68 | 15.46 | 14.38 | 10.49 | 6.51 | 10.94 | 12.59 | 16.10 | 11.82 | 16.51 | 16.78 | 16.59 | 12.99 | 18.86 | 20.04 | 21.33 | 15.36 | 19.80 | 18.36 | 17.17 | 11.78 | 16.18 | 16.14 | 15.91 | 11.44 | 16.15 | 16.46 | 16.67 | 10.61 | 15.59 | 15.86 | 17.87 | 18.39 | 24.29 | 25.22 | 25.28 | 17.60 | 24.36 | 25.22 | 25.28 | 18.72 | 6.76 | 6.35 | 5.61 |
Current Ratio |
8.4 | 9.1 | 9.6 | 8.5 | 8.6 | 9.0 | 8.9 | 7.5 | 7.0 | - | 7.4 | 7.0 | 7.9 | - | 9.0 | 8.4 | 8.8 | 8.7 | 8.6 | 7.9 | 7.9 | 7.9 | 7.9 | 6.7 | 6.7 | 6.7 | 6.7 | 6.8 | 6.8 | 6.8 | 6.8 | 5.8 | 5.8 | 5.8 | 5.8 | 9.2 | 9.2 | 9.2 | 9.2 | 8.3 | 8.3 | 8.3 | 8.3 | 6.8 | 6.8 | 6.8 | 6.8 | 8.8 | 8.8 | 8.8 | 8.8 | 8.5 | 8.5 | 8.5 | 8.5 | 7.3 | 7.3 | 7.3 | 7.3 |
DSO |
46.1 | 46.6 | 49.5 | - | 50.6 | 50.8 | 54.5 | - | - | - | 50.2 | - | 24.9 | - | 51.8 | 43.5 | 45.4 | 42.2 | 45.9 | 44.3 | 54.7 | 69.1 | 53.6 | 46.1 | 52.2 | 53.6 | 62.2 | 59.5 | 67.6 | 68.5 | 64.1 | 51.9 | 57.5 | 61.1 | 63.0 | 51.9 | 57.5 | 58.6 | 63.3 | 53.2 | 61.0 | 61.4 | 60.8 | 47.5 | 52.3 | 56.1 | 60.5 | 47.7 | 55.1 | 47.5 | 50.1 | 55.5 | 62.8 | 63.0 | 61.6 | 54.7 | 60.9 | 63.9 | - |
DIO |
186.7 | 178.7 | 174.4 | - | 196.8 | 192.1 | 178.2 | - | - | - | 143.9 | - | 75.6 | - | 118.4 | - | 122.0 | 118.8 | 138.0 | - | 155.3 | 157.2 | 151.2 | - | 158.6 | 159.9 | 150.7 | - | 134.0 | 134.7 | 116.9 | - | 92.0 | 96.2 | 92.1 | - | 84.9 | 83.5 | 84.3 | - | 79.0 | 76.8 | 81.7 | - | 87.5 | 98.8 | 110.4 | - | 115.2 | 94.6 | 77.6 | - | 75.1 | 73.9 | 76.5 | - | 84.4 | 85.9 | - |
DPO |
30.2 | 30.1 | 26.9 | - | 28.4 | 27.8 | 27.1 | - | - | - | 24.3 | - | 14.8 | - | 23.8 | - | 25.1 | 22.9 | 21.6 | - | 21.1 | 21.3 | 25.9 | - | 32.9 | 33.1 | 33.6 | - | 33.0 | 33.2 | 33.0 | - | 31.5 | 32.9 | 32.8 | - | 31.9 | 31.4 | 29.2 | - | 24.8 | 24.1 | 26.7 | - | 29.7 | 33.5 | 32.9 | - | 29.6 | 24.3 | 26.7 | - | 35.6 | 35.0 | 33.9 | - | 34.5 | 35.1 | - |
Operating Cycle |
232.8 | 225.3 | 223.9 | - | 247.5 | 242.9 | 232.7 | - | - | - | 194.2 | - | 100.5 | - | 170.2 | 43.5 | 167.3 | 161.0 | 183.9 | 44.3 | 210.0 | 226.3 | 204.7 | 46.1 | 210.8 | 213.4 | 212.9 | 59.5 | 201.6 | 203.2 | 181.0 | 51.9 | 149.5 | 157.3 | 155.1 | 51.9 | 142.4 | 142.1 | 147.6 | 53.2 | 140.0 | 138.2 | 142.5 | 47.5 | 139.8 | 154.9 | 170.9 | 47.7 | 170.3 | 142.1 | 127.7 | 55.5 | 137.9 | 136.8 | 138.1 | 54.7 | 145.2 | 149.8 | - |
Cash Conversion Cycle |
202.6 | 195.2 | 197.0 | - | 219.1 | 215.1 | 205.6 | - | - | - | 169.8 | - | 85.6 | - | 146.4 | 43.5 | 142.2 | 138.1 | 162.3 | 44.3 | 188.9 | 205.0 | 178.8 | 46.1 | 177.9 | 180.3 | 179.3 | 59.5 | 168.6 | 170.0 | 148.1 | 51.9 | 118.0 | 124.4 | 122.2 | 51.9 | 110.5 | 110.7 | 118.4 | 53.2 | 115.3 | 114.1 | 115.8 | 47.5 | 110.1 | 121.5 | 138.0 | 47.7 | 140.7 | 117.8 | 101.0 | 55.5 | 102.3 | 101.8 | 104.2 | 54.7 | 110.8 | 114.7 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Intuitive Surgical, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Baxter International
BAX
|
$ 17.13 | -0.06 % | $ 8.79 B | ||
|
AtriCure
ATRC
|
$ 27.64 | -2.09 % | $ 1.32 B | ||
|
BioLife Solutions
BLFS
|
$ 19.77 | 0.15 % | $ 911 M | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Haemonetics Corporation
HAE
|
$ 57.31 | 0.01 % | $ 2.88 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Alcon
ALC
|
$ 78.33 | 0.41 % | $ 40.4 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 9.33 | 3.44 % | $ 22.6 M | ||
|
The Cooper Companies
COO
|
$ 70.18 | -1.45 % | $ 14 B | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Repro Med Systems
KRMD
|
$ 4.22 | 0.24 % | $ 195 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Microbot Medical
MBOT
|
$ 2.36 | -9.07 % | $ 108 M | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Harvard Bioscience
HBIO
|
$ 4.5 | 4.41 % | $ 200 M | ||
|
electroCore
ECOR
|
$ 6.14 | 0.99 % | $ 52.1 K | ||
|
Masimo Corporation
MASI
|
$ 178.35 | 0.02 % | $ 9.51 B | ||
|
iRhythm Technologies
IRTC
|
$ 118.31 | 2.66 % | $ 3.79 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Milestone Scientific
MLSS
|
$ 0.28 | 2.33 % | $ 23 M | ||
|
Merit Medical Systems
MMSI
|
$ 68.7 | 0.64 % | $ 4.06 B | ||
|
Glaukos Corporation
GKOS
|
$ 116.88 | 0.36 % | $ 5.66 B | ||
|
ICU Medical
ICUI
|
$ 124.66 | -0.81 % | $ 3.07 B | ||
|
Retractable Technologies
RVP
|
$ 0.69 | 2.48 % | $ 20.7 M | ||
|
InfuSystem Holdings
INFU
|
$ 9.69 | 3.3 % | $ 200 M | ||
|
Envista Holdings Corporation
NVST
|
$ 26.27 | -0.49 % | $ 4.41 B | ||
|
STERIS plc
STE
|
$ 222.07 | -0.22 % | $ 21.9 B | ||
|
Teleflex Incorporated
TFX
|
$ 119.45 | 0.87 % | $ 5.33 B | ||
|
Pro-Dex
PDEX
|
$ 51.26 | -0.43 % | $ 169 M | ||
|
Utah Medical Products
UTMD
|
$ 66.0 | 0.15 % | $ 214 M | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
LeMaitre Vascular
LMAT
|
$ 113.23 | -1.21 % | $ 2.56 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.64 | -0.64 % | $ 2.32 B | ||
|
ResMed
RMD
|
$ 228.06 | -0.29 % | $ 33.3 B | ||
|
Pulse Biosciences
PLSE
|
$ 18.63 | -0.24 % | $ 1.26 B | ||
|
Stereotaxis
STXS
|
$ 1.91 | 2.14 % | $ 174 M | ||
|
STAAR Surgical Company
STAA
|
$ 26.46 | 0.06 % | $ 1.31 B | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
West Pharmaceutical Services
WST
|
$ 256.74 | 0.09 % | $ 18.6 B | ||
|
AngioDynamics
ANGO
|
$ 9.79 | -0.09 % | $ 400 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 153.19 | -0.62 % | $ 44.1 B | ||
|
Nephros
NEPH
|
$ 2.94 | -0.68 % | $ 30.5 M | ||
|
OraSure Technologies
OSUR
|
$ 3.01 | 1.69 % | $ 221 M | ||
|
Repligen Corporation
RGEN
|
$ 120.61 | 0.42 % | $ 6.72 M |